Logo
x

Search category

Subscribe Now

Shionogi

Shionogi Initiated P-I/II/III Clinical Trial (Part 2) and P-III Additional Dose Clinical Trial of S-268019 for COVID-19

Shionogi Initiated P-I/II/III Clinical Trial (Part 2) and P-III Additional Dose Clinical Trial of S-268019 for COVID-19

  • January 17, 2023
Shionogi Seeks Japan Approval of S-268019 for the Treatment of COVID-19

Shionogi Seeks Japan Approval of S-268019 for the Treatment of COVID-19

  • November 24, 2022
Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacteria...

  • November 7, 2022
Shionogi Presents Real-World Evidence of Fetroja (cefiderocol) for Treatment Resistant Bacterial Infections at IDWeek 2022

Shionogi Presents Real-World Evidence of Fetroja (cefiderocol) for Treatment Resistant Bacterial Infections at IDWeek 2022

  • October 20, 2022
Shionogi Presents Results of S-217622 in P-IIb Study for the Treatment of COVID-19 at ECCMID 2022

Shionogi Presents Results of S-217622 in P-IIb Study for the Treatment of COVID-19 at ECCMID 2022

  • April 25, 2022
Shionogi Entered into a Commercialization Agreement with Susmed for Digital Therapeutic App to Treat Insomnia

Shionogi Entered into a Commercialization Agreement with Susmed for Digital Therapeutic App to Treat Insomnia

  • December 28, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.